N-Terminal Modification of Gly-His-Tagged Proteins with Azidogluconolactone
ChemBioChem
(
IF3.2
)
Pub Date : 2021-09-14, DOI: 10.1002/cbic.202100381
Karl D Brune
1,
2
,
Ilva Liekniņa
3
,
Grigorij Sutov
1,
4
,
Alexander R Morris
1,
4,
5
,
Dejana Jovicevic
1
,
Gints Kalniņš
3
,
Andris Kazāks
3
,
Rihards Kluga
6,
7
,
Sabine Kastaljana
6,
7
,
Anna Zajakina
3
,
Juris Jansons
3
,
Dace Skrastiņa
3
,
Karīna Spunde
3
,
Alexander A Cohen
8
,
Pamela J Bjorkman
8
,
Howard R Morris
5,
9
,
Edgars Suna
6,
7
,
Kaspars Tārs
3,
7
Affiliation
Genie Biotech Ltd., Lido Medical Centre, St. Saviour, JE2 7LA, United Kingdom.
Department of Bioengineering, Imperial College London, London, SW7 2AZ, UK.
Latvian Biomedical Research and Study Centre, Ratsupites 1, 1067, Riga, Latvia.
Lab Group LT, UAB, Vilnius, Lithuania.
BioPharmaSpec Ltd., Suite 3.1, Lido Medical Centre, St. Saviour, JE2 7LA, UK.
Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006, Riga, Latvia.
University of Latvia, Jelgavas 1, 1004, Riga, Latvia.
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK.
Site-selective α-amino acylation of proteins with N-terminal Gly-HisTags using 6-azido-6-deoxy-glucono-1,5-lactone (6AGDL) is reported. To demonstrate the usefulness of this reaction, we multimerise the SARS-CoV-2 receptor-binding domain (RBD) protein antigen onto virus-like particles (VLPs) via strain-promoted alkyne-azide cycloaddition (SPAAC). The resulting COVID-19 vaccine candidate induces single-shot seroconversion, and virus-neutralizing antibodies in mice.
京公网安备 11010802027423号